CompuMed drifts lower as borrow costs quietly rebound
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
CMPD is a micro-cap health care technology company trading on the OTC Pink market. This week the stock closed at $6.22, down about 5% on the week despite a 6.3% bounce on Wednesday alone. With a market cap of roughly $7.8 million, thin liquidity defines nearly every aspect of this name's trading profile.
The most notable development this week is the cost to borrow. After sliding sharply from above 5% in mid-March to just 1.4% by April 1, borrowing costs have more than tripled over the past month, climbing back to 4.3% as of April 28. That rebound — up about 1.5% on the week — suggests renewed demand for borrows despite the stock's recent price weakness. Availability, however, tells a very different story: at 9,999% of short interest, the lending pool is effectively unrestricted. There are vastly more shares available to borrow than are currently shorted, so the borrow-cost move is not being driven by a shortage of supply.
Short positioning is modest and not a primary driver. Short interest amounts to just 0.41% of the free float — roughly 5,475 shares in absolute terms — and has edged up 6% over the past week after falling 17% over the prior month. The mid-March short interest peak, when shares short ran near 6,600, has been unwound. What remains is a residual, low-conviction position. The ORTEX short score of 31.7 out of 100 is consistent with that picture: no meaningful short-side pressure.
With no analyst coverage, no upcoming earnings on the calendar, and insider data last recorded in 2007, the story on CMPD this week is largely one of thin-market mechanics. The stock's one-month decline of 7% has come without any obvious catalyst in the news flow, and the only recent headline tagged to the company was a general hospital-care licensing industry roundup from late April. Factor scores and valuation multiples flagged in the data are too stale to be meaningful — the most recent valuation data dates to 2012.
The price action itself is the main thing to watch. The intraday swings — a 6% single-day move in either direction is not unusual for a name this size — can be driven by very small order flow. The borrow-cost trajectory, and whether it continues to climb back toward the February highs above 5%, is the one data point worth monitoring for any sign that positioning is changing.
Stocks in this article
See the live data behind this article on ORTEX.
Open CMPD on ORTEX →How this article was generated
- Generated
- 30 Apr 2026, 01:48
- Data as of
- 30 Apr 2026, 01:47
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowEarningsORTEX Alpha signals
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.